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ABSTRACT 
 
Internationally, investment in the availability of routine healthcare data for improving health, 
health surveillance and healthcare is increasing. We assessed the validity of hospital episode 
data for identifying individuals with chronic kidney disease (CKD) compared to biochemistry 
data in a large population-based cohort, GLOMMS-II (n=70,435). GLOMMS-II links 
hospital episode data to biochemistry data for all adults in a health region with impaired 
kidney function and random samples of individuals with normal and unmeasured kidney 
function in 2003. We compared identification of individuals with CKD by hospital episode 
data (based on ICD-10 codes) to the reference standard of biochemistry data (at least two 
estimated glomerular filtration rates <60 ml/min/1.73m2 at least 90 days apart). Hospital 
episode data, compared to biochemistry data, identified a lower prevalence of CKD, had low 
sensitivity (<10%) but high specificity (>97%). Using routine health care data from multiple 
sources offers the best opportunity to identify individuals with CKD. 
 
INTRODUCTION 
Chronic kidney disease (CKD) has been identified as a worldwide public health problem with 
a rising incidence and prevalence1, and is associated with high morbidity (cardiovascular 
disease, need for renal replacement therapy (RRT)), mortality and health care costs 
(estimated for England 2009-10 to be £1.45 billion2). Risk factors for CKD include diabetes, 
vascular disease, hereditary renal diseases, smoking and hypertension. In 2002, the Kidney 
Disease Outcomes Quality Initiative (KDOQI) defined and classified CKD based on kidney 
damage (structural or functional abnormalities of the kidney)  with glomerular filtration rate 
(GFR, a measure of kidney function) ≥60 ml/min/1.73m2 (stage 1-2) or GFR <60 
ml/min/1.73m2 alone (stage 3-5), present for at least three months1.  Estimates of prevalence, 
based on the first part of this definition, in the US suggest the prevalence of CKD stages 1-4 
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increased from 10.0% in 1988-1994 to 13.1% in 1999-2004.3 However, other studies have 
reported varied prevalence rates of CKD (0.6% to 42.6).4 In UK general practices only 2.9% 
are registered as having CKD.5 Part of the variation in prevalence estimates may be due to 
how CKD is defined and the data sources used to identify individuals with CKD.  
 
For many conditions, information on disease prevalence is estimated from disease registries, 
GP registers and/or coding of hospital episodes. The use of hospital episode data (recorded in 
Scotland as the Scottish Morbidity Record (SMR) 01), either as single episodes or 
longitudinally linked episodes to identify comorbidities has been used extensively in 
research.6 For acute events that almost exclusively require hospital admission (e.g. hip 
fracture) this may be a valid source of information.7. For chronic diseases such as CKD, 
hospital episode data may require supplementation from other sources of data to fully 
elucidate disease load, and facilitate early identification. The UK government and others 
internationally, have invested in routine health care data (ie funding opportunities, investment 
in digital health systems) since it is thought to be important for health and health care through 
research, health surveillance and health care planning.8-12 
 
For individuals with CKD, early detection and management is believed to be important to 
reduce morbidity and slow progression to RRT.13 However, the forum of care may vary, with 
all patients requiring GP care and more advanced patients potentially requiring assessment by 
nephrology care.  In the UK, there is no standard surveillance system for the identification of 
people with CKD. Ideally those with CKD would be identified clinically from a combination 
of sources including biochemistry testing for estimated GFR (eGFR) and albuminuria, 
however this relies on clinicians identifying and noting abnormal results and that these are 
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sustained abnormalities rather than an acute change. This is sometimes difficult to achieve in 
regions where biochemistry testing is done by multiple providers and where not all results are 
returned to a single clinician responsible for compiling results. An alternative means of 
identifying those with CKD would be to flag those that have routine hospital episode data 
consistent with this CKD diagnosis and subsequently informing GPs for follow-up and 
confirmation. 
 
 
Two recent systematic reviews14, 15, and recent studies16-19, have evaluated the degree to 
which administrative coding accurately identified individuals with kidney diseases, reporting 
a large variation in sensitivity (3%-88%). Only a few studies have compared hospital 
administrative data to laboratory data employing the 2002 KDOQI definition of stages 3-5 
CKD, of at least two eGFR <60 ml/min/1.73m2 at least 90 days apart.18, 20, 21  Of these, only 
Ronksley et al.18 did so in a community cohort, in Canada. Using a community based 
population increases the generalisability of results as opposed to relying on, for example, a 
selected inpatient population. We did not identify any studies from the UK that compared 
hospital episode data to laboratory data. 
 
With the growing emphasis on the use of routine administrative data, validation studies 
become increasingly important in order to provide information on the accuracy and validity 
of findings that are based exclusively on these data. As administrative data have the potential 
to be a rich source of data for population-based research in CKD, we aimed to assess the 
validity of diagnostic algorithms for CKD in hospital episode data compared to biochemistry 
data in a large population-based cohort in Grampian, Scotland. 
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 METHODS 
We carried out a validation study within an existing cohort developed by data linkage of 
biochemistry, hospital episode and death registry data. 
 
Study Population – Grampian Laboratory Outcomes, Morbidity and Mortality Study-II 
(GLOMMS-II) cohort 
All inpatient, out-patient and community serum creatinine (isotope dilution mass 
spectrometry (IDMS) aligned) and urinary protein measurements in the Grampian region, 
served by a single United Kingdom National External Quality Assessment Service monitored 
biochemistry service, are contained in the Grampian Laboratory Renal Database for 1999 to 
2009. This database was queried to identify the GLOMMS-II cohort, which was comprised 
of: all adults (>15 years) with impaired kidney function in 2003; a random sample of 
individuals with normal or no measure of kidney function in 2003 (but prior and post 2003 
sampling); all those with proteinuria but normal kidney function in 2003; and all individuals 
on renal replacement therapy (RRT) at 1 January 2003 (identified from Scottish Renal 
Registry and local renal system). Where present, the first “low” eGFR <60 ml/min/1.73m2 in 
2003 was taken as the index value and date. Where all values in 2003 were normal the last 
value and date were taken as the index. Where no samples were taken in 2003, the index date 
was taken as 31 December 2003 to allow the potential for the individual to be sampled. 
    
Defining CKD from biochemistry data 
 
eGFR was calculated using the 4 variable IDMS aligned Modification of Diet in Renal 
Disease (MDRD) formula (serum creatinine, age, sex and race). CKD was defined and staged 
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according to KDOQI.1 CKD stage 3-5 (including 3a and 3b) was defined as an index 
eGFR<60ml/min/1.73m2 in 2003 followed after 90 days by another low eGFR 
(<60ml/min/1.73m2), or if there were no further eGFR values after 90 days post-index, the 
last eGFR prior to 90 days pre-index also being low i.e. between the start of the database 
records in 1999 and the index value. CKD stages 1 and 2 were defined as an index eGFR 
>60ml/min/1.73m2 with microalbuminuria or macroalbuminuria on urine albumin or protein 
creatinine ratio (ACR or PCR) testing. Individuals were categorised as not having CKD if 
their index eGFR was not measured, was normal or was impaired but not CKD (at least one 
eGFR <60ml/min/1.73m2 but with no evidence that this was sustained for at least three 
months). 
 
Defining CKD from hospital episode data 
In the UK, information about an episode of hospital care is recorded following a patient’s 
discharge.  In Scotland, this information is recorded in the SMR01, which is collated 
nationally by the Information Services Division (ISD), part of NHS National Services 
Scotland.  SMR01 is an episode-based patient record relating to all inpatient and day case 
discharges. This information contributes to NHSScotland’s Performance Assessment 
Framework, clinical governance and performance indicators, and for planning and research 
purposes.22 Diagnoses are coded using International Classification of Disease-10 (ICD-10) 
and procedures coded using the Office of Population Censuses and Surveys Classification of 
Interventions and Procedures (OPCS). We defined CKD for each patient from hospital 
episode data for two time periods; 2003 (including admission at index) and also adding a five 
year “look-back” period. 
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To identify potentially relevant codes to define CKD, an experienced nephrologist reviewed 
all ICD-10 and OPCS codes.  Three groups of codes (algorithms) were developed (Table 1): 
first, a broad definition encompassing most diseases which might include renal complications 
(“All codes”); second, an algorithm to define renal disease based on a Charlson comorbidity 
algorithm23 (“renal disease”); and third, an algorithm highly likely to identify CKD (“chronic 
kidney disease”).
7 
 
Table 1:  Renal disease-related ICD-10 and OPCS codes (algorithms) 
 
ICD, International Classification of Diseases; OPCS, Office of Population Censuses and Surveys Classification of 
Interventions and Procedures 
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Data linkage 
The Community Health Index (CHI) number, a unique patient identifier used throughout the 
Scottish health care system, was used to link GLOMMS-II with hospital episode data  using 
deterministic matching. Patient identifiers were removed after data linkage.  The dataset was 
stored in the Grampian Data Safe Haven allowing secure controlled access for researchers 
while ensuring data security.24 
 
The flow diagram for generating GLOMMS-II is shown in Figure 1.  From the database 
query 71,251 individuals were identified. There were 471 excluded from the analysis because 
of missing information on index date, duplication or death on index date.  The 345 people 
already on RRT at index (thus end stage renal disease, not just CKD), were excluded from the 
analysis (74.8% had a “CKD” code from SMR01).  Overall, 70,435 individuals were 
included in this study. 
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Figure 1: GLOMMS-II flow diagram 
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Statistical Analysis  
Descriptive statistics were used to describe demographic, proteinuria/albuminuria status, 
creatinine, eGFR and comorbidity variables stratified by renal risk group (CKD stage 1-
5/normal eGFR, impaired eGFR or eGFR not measured). Comorbidity was based on the 
Charlson comorbidity index25, which is a weighted index that takes into account the number 
and seriousness of comorbid disease. The proportion of the cohort with CKD identified by 
biochemistry data and the proportion of the cohort with CKD identified by hospital episode 
data were calculated. The validity of hospital episode data identified CKD was assessed for 
the three coding algorithms and two time periods; 2003 (including admission at index) and 
also adding a five year “look-back” period.   
 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were calculated against the reference standard of CKD (biochemistry data).   Kappa values, κ 
(a measure of agreement between two sets of categorical measurements on the same 
individuals)26, were calculated. We categorised agreement as poor if κ 0.20, fair if 0.21≤ κ≤ 
0.40, moderate if 0.41≤ κ≤ 0.60, substantial if 0.61≤ κ≤ 0.80 and good if κ>0.80.27 
 
The validity of hospital episode data-defined CKD within specific subgroups was considered, 
including CKD stage (stage 1-2, 3a, 3b, 4 and 5) and age (<75 or ≥75 years). To explore 
sensitivity further, analyses were repeated comparing hospital episode data to an alternative 
definition for biochemistry-defined CKD, which excluded those with impaired eGFR and 
those with eGFR not measured from the no-CKD definition. Analyses were performed using 
Stata version 1328 and Microsoft Excel. 
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RESULTS 
A total of 70,435 individuals were included.  The characteristics of the study population are 
shown in Table 2. Based on biochemistry data, 28% (19,694) of the cohort had CKD stage 1-
5 (which equates to 4.5% of the adult Grampian population in 2003 (433,109)29). Overall, the 
median age of the cohort was 63.3 years and 58.4% were female. As expected, those with 
CKD were older than those with normal eGFR or "not measured". Charlson comorbidity 
categories for CKD Stage 1-5 and impaired eGFR were similarly distributed with more than 
two-thirds of individuals with a score of zero.  Those with normal eGFR or "not measured" in 
2003 had the lowest Charlson scores. Of note, there were 63 individuals with 
macroalbuminuria but no eGFR measured. Of those with CKD identified by biochemistry, 
6,767 individuals had no hospital admission in the five years prior to 2003.  
 
As shown in Table 3, based on the reference standard of biochemistry-defined CKD, 28% 
(19,694) of the cohort had CKD stage 1-5. The proportion of the cohort identified with 
probable CKD by hospital episode data was substantially lower, ranging from 0.8% to 4.1% 
over the three coding algorithms and two time periods. 
 
Hospital episode data identified CKD was generally less common compared to biochemistry-
defined CKD, and varied across coding algorithms and time periods (Table 3). The sensitivity 
of hospital episode coding compared to biochemistry for identifying CKD was low, ranging 
from 2.2% to 8.6%. Specificity of coding was >97% for all coding algorithms and time 
periods.  All algorithms improved by adding a five year look-back period in addition to just 
SMR01 records from 2003, showing higher sensitivities. The very inclusive “all codes” 
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algorithm was most sensitive but least specific, followed by the “renal disease” and “chronic 
kidney disease” algorithm which was most specific. Overall the agreement between hospital 
episode data and biochemistry defined CKD was very poor (kappa values <0.1) because of 
low numbers identified with hospital episode data, despite excellent specificity. 
 
Sensitivity analyses were carried out comparing hospital episode data to an alternative 
definition for biochemistry-defined CKD, excluding those with impaired eGFR and those 
with eGFR not measured from the no-CKD definition.  However, this, as expected, only 
improved the PPV further and reduced the NPV further of hospital episode data. For those 
with CKD algorithm defined CKD using 2003 plus five year look-back data, PPV 99.56% (vs 
81.06%) and NPV 51.05% (vs 72.68%). 
 
Using the “renal disease” and “CKD” coding algorithms, since more specific, including the 
five-year look-back period, the performance within age and CKD stage subgroups was 
considered (Table 4). Amongst those with biochemistry identified CKD, the “renal disease” 
algorithm identified similar but slightly more individuals than the “CKD” algorithm.  Worse 
CKD stage was associated with better identification (sensitivity) using both hospital episode 
based algorithms (4.8% of stage 3b compared to 56.9% of stage 5 CKD, for the “CKD” 
algorithm).  For biochemistry identified CKD stage 3b to 5, younger age (<75 vs ≥75 years) 
was associated with a higher sensitivity using the hospital episode recording algorithms. 
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Table 2: Characteristics of study population 
 
 
CKD, chronic kidney disease; eGFR, glomerular filtration rate; IQR, interquartile range; PCR, protein-
creatinine ratio; ACR, albumin-creatinine ratio 
Renal risk groups based on biochemistry data 
 
14 
 
Table 3: Validity of hospital episode data definition for chronic kidney disease compared to the reference standard of biochemistry 
 
HE, hospital episode; CKD, chronic kidney disease; PPV, positive predictive value; NPV, negative predictive value 
*Interpretation of kappa: Agreement poor if κ≤0.20, fair if 0.21≤κ≤0.40, moderate if 0.41≤κ≤0.60, substantial if 0.61≤κ≤0.80 and good if κ>0.80. 
Biochemistry definition of CKD/no CKD: Stage 1-5/normal, impaired or not measured (see Methods section). 
Hospital episode coding (SMR01) definition of CKD/no CKD: ICD and OPCS codes as detailed in Table 1/no coding or no admission (see Methods section). 
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Table 4:  Validity of hospital episode coding definition (2003 +5 year look-back) for chronic kidney 
disease compared to the reference standard of biochemistry by stage and age group 
 
HE, hospital episode. 
Biochemistry definition of CKD/no CKD: Stage 1-5/normal, impaired or not measured (see Methods section). 
Hospital episode coding (SMR01) definition of CKD/no CKD: ICD and OPCS codes as detailed in Table 1/no 
coding or no admission (see Methods section).
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DISCUSSION 
 
We used a large UK community cohort to demonstrate whether the use of coding algorithms 
to identify renal disease, in particular CKD, from hospital episode data was a useful 
alternative should biochemistry data be difficult to access. We found that hospital episode 
data coding algorithms were very specific for CKD, however sensitivities were very poor (at 
best only 8.6% identified), as was agreement. Of interest the proportion of those with CKD 
identified through biochemistry data who were also identified with hospital episode coding 
was higher at more advanced CKD stages and in those under 75 years of age.  
 
 
CKD is recorded poorly in hospital episode data.  This may be because CKD is often not the 
main reason for admission.  This is likely to be similar for other chronic diseases such as 
diabetes and hypertension, unlike acute events such as hip fracture. Also, the recognition of 
CKD in the time prior to eGFR reporting (2008) was poor, and may have improved in the 
time since then. Those with more advanced renal disease are also more likely to be frequent 
in-patients as a result of the higher comorbidity load30 and as a result of increased 
complications of their renal disease, thus the more likely that renal disease will be recognised 
during the admission episode coding. 
 
Comparison with existing literature 
Few studies18, 20, 21 have validated hospital administrative data compared with a reference 
standard of biochemistry data employing the KDOQI definition of CKD, of at least two 
eGFR <60 ml/min/1.73m2 at least 90 days apart, and none included CKD stage 1 and 2 (those 
with proteinuria). In keeping with our findings, where reported, sensitivities are low and 
specificities high for hospital episode data compared to biochemistry defined CKD.14, 15, 18, 19 
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We also found high PPVs, which means that individuals who are identified as having CKD 
from hospital episode coding, do have CKD according to biochemistry data, thus any 
diagnosis based on coding should be accurate using the algorithms outlined, although very 
un-sensitive. The range of PPV values reported in other CKD validation studies has been 
broad (29%-100%).15, 18 
 
Our study used a very large population-based cohort.  Only one other study has used a 
community based population.18  However, Ronksley et al. looked for hospital episode data 
after the biochemistry identification of CKD.  Therefore they were assessing whether those 
with CKD were being identified at their next hospital admission, not whether a prevalence 
cohort with CKD was identifiable equally from biochemistry or hospital episode coding.18 
This use of a three year window after biochemistry identified disease would perhaps identify 
patients too late for intervention, thus our method is perhaps more applicable for identifying 
those with disease. 
 
We have demonstrated that those with more advanced CKD are more likely to be captured by 
hospital episode data, also reported by others.18, 21  This is in keeping with the fact that at the 
time of this study, eGFR reporting had not been instigated in the UK and as such, the 
identification of CKD would be expected only in those with more advanced CKD, both by 
clinicians and SMR01 coders. Ronksley et al. reported that estimates of sensitivity were 
higher when eGFR <30 mL/min/1.73m2 was used as the reference standard compared with 
using <60 mL/min/1.73m2.18 Ferris et al. reported a similar pattern in in-patients.21  
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Studies have reported that older age was not significantly associated with a greater likelihood 
of being labelled with CKD.21 However, this was a study of inpatients, therefore the risk 
profile identified with biochemistry might have been different. Our finding that younger 
individuals with CKD were identified better on hospital episode data than older individuals 
has been previously reported.18 For younger individuals, CKD is likely to be more of a 
significant problem than for those that are elderly with CKD with the same degree of renal 
impairment. It may also reflect that those with CKD at younger ages are likely to have fewer 
comorbidites when admitted to hospital and therefore have this recognised when discharge 
coding is carried out.31 
 
Denburg et al.17 looked at the recording of biochemistry results at a general practice level 
compared to the recognition of CKD on general practice coding, which again found low 
sensitivity but excellent specificity and high PPV.  It is unclear, however, how many of the 
biochemistry results had been entered into GP systems manually. 
 
Strengths and limitations 
This study has many strengths. It is one of only a few studies assessing agreement between 
biochemistry defined CKD that was required to be present for greater than three months 
compared to hospital episode data.18, 20, 21 It is a very large population-based cohort, not 
limited to a specific patient group, and since ICD-10 coding is used, we might expect these 
findings to be potentially generalisable to other chronic diseases, eg diabetes, and across the 
world. The universal nature of the biochemistry service to the region ensures that those living 
within the region who have testing of renal function would have results available for 
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consideration, and where repeated these would be available, assisting in the identification of 
those with truly chronic kidney disease. 
 
There are, however, limitations to this study. Calculating eGFR using the MDRD equation is 
reflective of current UK practice and thus the individuals currently identified as having CKD, 
however there are others outside of the UK who support the use of the CKD-EPI equation. It 
would be expected that both eGFR equations would identify similar individuals with CKD, 
particularly at more advanced stages, and it is unlikely that the results would be significantly 
different.31 The use of only hospital episode data as a source of confirmatory CKD recording, 
although fulfilling the aim of this paper to ascertain its validity, meant that other routine 
sources of such data such as GP coding, were not assessed. Although this would be a useful 
additional source of data, it was not available to us, would require assessment in its own 
right, and has been explored at least at a GP biochemistry recording level before.17 Our 
biochemistry definition of no-CKD was all-inclusive, including impaired eGFR (at least one 
eGFR <60ml/min/1.73m2 but not sustained) and eGFR not measured. However, we 
performed sensitivity analyses, defining “no CKD” as those with normal eGFR only and 
found that this only improved PPV and worsened NPV. Sensitivity and specificity were 
similar. As noted previously, the recognition of CKD in the time prior to eGFR reporting 
(2008) was poor, and may have improved in the since then. However, this is unlikely to 
change the greater sensitivity of eGFR reporting over SMR01. 
 
Implications for future research or clinical practice 
As mentioned in the introduction, hospital episode data may be sufficient for acute hospital 
care requiring events.  However, for chronic conditions, as illustrated here with CKD, the use 
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of corroborating additional data when admissions are due to another event or comorbidity 
may be necessary. 
 
 
As demonstrated, hospital episode coding data is very specific with high PPV for the 
identification of individuals with CKD.  This has implications for both clinical practice and 
future research.  With clinical practice, it is insufficient to use hospital episode data alone to 
identify those with CKD, and access to current and historical biochemistry data is essential to 
identifying CKD appropriately.  However, the use of hospital episode data as an additional 
flag is potentially useful for identifying high risk individuals.  Another issue for clinical 
practice is patient safety, particularly with the prescribing of drugs that are either nephrotoxic 
or with significant renal clearance.  The use of both systems of identification should improve 
patient safety issues related to this.  This also applies to preparation for surgical, radiological 
and oncological procedures. 
 
For research, we have demonstrated that biochemistry data is crucial for describing the 
prevalence of CKD and therefore the healthcare burden associated with it, not just the few 
identified through hospital episode data.  Historically, CKD identified through hospital 
episode coding described high RRT initiation rates.  However, in cohorts identified through 
biochemistry more recently, the rates reported have been lower.32  Whether this is due to the 
severity of CKD identified being different, or due to the disease processes being different, is 
not clear and requires further research.  There are also implications for clinical trials, in that 
the event rate that sample sizes are based on may differ depending on the source of CKD 
identification. 
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The ideal for the future would be a unifying electronic patient healthcare record containing 
information on previous hospital identified events, general practice and also biochemistry 
results, to ensure accurate and timely identification of those with CKD. 
 
Conclusion 
The findings of this study suggest that routine hospital episode data has limited value in the 
routine identification of individuals with CKD. However where those with CKD have been 
identified using hospital episode data, this information is highly specific. Other sources of 
routine health care data such as routine biochemistry data, including historical data, and not 
just that pertaining to a given event, should be available to clinicians caring for patients, and 
are an important source for further research into clinical outcomes, including hospitalisations.   
The most important uses of this data are for planning, surveillance, screening, and for 
research. 
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